The centerpiece of the acquisition is Ohtuvayre, a treatment for chronic obstructive pulmonary disease that secured U.S. approval last year. The drug’s commercial launch has exceeded Wall Street ...

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...

When female athletes collapse on the playing field, they are less likely to be resuscitated than men: How gender differences ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...

Technology will soon make it possible to develop cheap, widely accessible psychoactive substances that are not harmful in the ...

Hype around a Microsoft AI agent's ability to diagnose difficult cases misses the mark and overlooks real innovation, experts ...

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

From my colleague Andrew Joseph: Novartis said today that Swiss regulators have approved its malaria medicine Coartem for newborns and young infants, extending a long-standing treatment to the ...

Pervasive stigma around cannabis use is leading some ER doctors to overdiagnose a rare marijuana-related syndrome.

Six major medical groups, and a pregnant physician, are suing HHS Secretary Robert F. Kennedy Jr. over changes he made to ...